Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies that combine metabolic and pathway-targeted approaches. Its current work centers on PIKTOR, an investigational all-oral program built around multi-node inhibition of the PI3K/AKT/mTOR pathway for endometrial and breast cancer. The company’s platform is designed to pair therapeutic molecules with precision nutrition and related treatment strategies, reflecting its emphasis on cancer metabolism and tumor-specific vulnerabilities. Faeth Therapeutics also advances research aimed at improving outcomes for patients with solid tumors through clinically tested combinations and supportive digital tools. In today’s oncology market, the company occupies a specialized role at the intersection of biotechnology, metabolic intervention, and precision medicine.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Anand Parikh Esq., J.D.

Employees

29

Headquarters

Rockville, MD, United States

Website

www.faeththerapeutics.com